Date: July 9, 2020
Revive Therapeutics is a life sciences company. They're focusing on the research and development of therapeutics for rare disorders and infectious diseases. The Company has a strong patent and license portfolio that focuses on Infectious Diseases, Psychedelics, and CBD.
Revive's cannabinoid pharmaceutical portfolio concentrates on rare inflammatory areas such as liver disease. Further, the Company was granted FDA orphan drug status designation for the use of CBD to treat auto-immune hepatitis (liver disease) and FDA orphan drug status designation for the use of CBD to treat ischemia and reperfusion injury from organ transplantation.
With its recent acquisition of Psilocin Pharma Corp., Revive will advance Psilocybin-based therapeutics in various diseases and disorders and will prioritize development efforts to take advantage of several regulatory incentives awarded by the FDA such as Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease designations. The Company is also exploring the use of Bucillamine for the potential treatment of infectious diseases, including COVID-19.
For more information on Revive Therapeutics Ltd. (CSE: RVV) please fill out the form below.